AVTX
Avalo Therapeutics, Inc.
Avalo Therapeutics (AVTX) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- GAAP EPS −$0.83, up from −$1.92 a year ago.
- Avalo reported a net loss of $36.4 million for the second quarter of 2026.
- Research and development expenses rose to $23.4 million, driven by abdakibart development costs.
- The company ended the quarter with $472.2 million in cash, equivalents, and investments.
- Management expects current cash resources to fund operations into 2029.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP
Reported · GAAP diluted EPS
−$0.83
Consensus not captured before release
Prior year: −$1.92
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company reported no revenue for the quarter.
- Operating expenses increased significantly due to higher R&D and administrative costs.
Read original report
Source: Avalo Therapeutics, Inc. press release · SEC Form 8-K exhibit 99.1